newsfilter
← Latest News
Business Wire·

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for